Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...

Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.

metastatic breast cancer who received multiple lines of prior treatment, and was headlined at last year's ASCO congress. In the 557-patient study, Enhertu reduced the risk of disease progression ...

"This submission builds on our existing indication for Enhertu in patients with HER2 low metastatic breast cancer and an expanded approval would enable the potential for use in an earlier disease ...

Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer: Tokyo Saturday, February 1, 2025, 12:30 Hrs [IST] ...

Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...

The former Kate Middleton was diagnosed with cancer early in 2024, and much speculation about the state of her health has followed. Catherine, Princess of Wales, has since shared that she ...

Metastatic breast cancer patients often face unique emotional and psychological challenges as they navigate a diagnosis that is both life-changing ...

Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HER2-ultralow status in HR-positive, HER2-negative ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.